Clofibric acid treatment for 10 weeks significantly reduced the percent of glomeruli with focal glomerulosclerosis compared to untreated rats (5% vs 24%, p<0.01).
Does pharmacologic lipid-lowering reduce glomerular injury in a rat 5/6 nephrectomy model of chronic renal failure?
Pharmacologic lipid-lowering with clofibric acid or mevinolin reduces glomerular injury and albuminuria in a rat model of chronic renal failure without altering systemic or glomerular hemodynamics.
Absolute Event Rate: 5% vs 24%
p-value: p=<0.01
The role of lipid abnormalities in the pathogenesis of focal glomerulosclerosis was investigated in the rat remnant kidney model of chronic renal failure. Rats subjected to right nephrectomy and two-thirds segmental infarction of the left kidney (5/6 nephrectomy) were treated for 10 weeks with the lipid-lowering agent clofibric acid. Both serum cholesterol and urine albumin excretion were significantly reduced by clofibric acid. At 10 weeks, the percent of glomeruli with focal glomerulosclerosis was 5 +/- 2% in clofibric acid-treated and 24 +/- 5% in untreated 5/6 nephrectomy rats (p less than 0.01). Inulin clearance was greater in clofibric acid-treated than in untreated 5/6 nephrectomy rats (0.28 +/- 0.02 versus 0.22 +/- 0.02 ml/min 100 g body wt, p less than 0.05). Body weight, kidney weight, and systemic blood pressure were not significantly altered by clofibric acid. Micropuncture studies, performed in separate groups of clofibric acid-treated and untreated 5/6 nephrectomy rats, demonstrated elevated single nephron glomerular filtration rates and glomerular capillary pressures 4 weeks after surgery. However, clofibric acid did not significantly alter single nephron glomerular filtration rates (95 +/- 2.1 nl/min in treated versus 97.0 +/- 6.2 nl/min in untreated, p greater than 0.05) or glomerular capillary pressures (56.6 +/- 1.5 mm Hg in treated versus 57.8 +/- 0.8 mm Hg in untreated, p greater than 0.05) in 5/6 nephrectomy rats. In a separate set of experiments, 5/6 nephrectomy rats were treated with the specific cholesterol synthesis inhibitor, mevinolin. Mevinolin improved serum lipid levels and reduced albuminuria in 5/6 nephrectomy rats without causing significant alterations in blood pressure.(ABSTRACT TRUNCATED AT 250 WORDS)
Kasiske et al. (Mon,) conducted a other in Chronic renal failure (focal glomerulosclerosis). Clofibric acid vs. Untreated 5/6 nephrectomy rats was evaluated on Percent of glomeruli with focal glomerulosclerosis (p=<0.01). Clofibric acid treatment for 10 weeks significantly reduced the percent of glomeruli with focal glomerulosclerosis compared to untreated rats (5% vs 24%, p<0.01).